Alonso Valeria
Centro de Estudios de Estado y Sociedad (CEDES), Sánchez de Bustamante 27, (1173) Buenos Aires, Argentina.
Rev Panam Salud Publica. 2003 Jun;13(6):400-6. doi: 10.1590/s1020-49892003000500009.
To assess the level of equity in drug consumption patterns in the Metropolitan Area of Buenos Aires, Argentina, given the transformation of the Argentine pharmaceutical market since the deregulation of the country's economy in 1991.
For this study, data from secondary statistical sources were processed and analyzed. The secondary sources used were two household surveys that contained a module on the utilization of health services and the associated expenditures. The surveys had been designed by the Ministry of Health and were applied in the Metropolitan Area of Buenos Aires in 1989 and 1995.
There was a socially regressive increase in out-of-pocket expenditures on drugs between 1989 and 1995, in a market where average drug prices doubled in the midst of relaxed price controls and more open imports. The regressive character of drug expenditures was shown in the growth in direct spending for drug purchases, the increase in the proportion of private health expenditures devoted to drugs, and the unequal increase among the different economic strata in the proportion of family income going toward drugs.
Out-of-pocket expenditures on drugs are an efficient indicator of equity for studying the financial protections that urban Argentines have when they become ill. This kind of indicator of financial equity could help improve the regulatory framework of the pharmaceutical market by incorporating social evaluation criteria along with analyses of pharmaceutical safety and therapeutic efficacy.
鉴于自1991年阿根廷经济放松管制以来该国药品市场的转变,评估阿根廷布宜诺斯艾利斯大都市区药品消费模式的公平程度。
本研究对二级统计来源的数据进行了处理和分析。所使用的二级来源是两项家庭调查,其中包含一个关于卫生服务利用及相关支出的模块。这些调查由卫生部设计,并于1989年和1995年在布宜诺斯艾利斯大都市区实施。
在1989年至1995年期间,药品自付费用出现了社会层面上的递减式增长,当时的药品市场处于价格管制放松和进口更加开放的环境中,平均药品价格翻了一番。药品支出的递减特征体现在药品购买直接支出的增长、私人卫生支出中用于药品的比例增加,以及不同经济阶层家庭收入用于药品的比例增长不均衡。
药品自付费用是研究阿根廷城市居民患病时所享有的经济保障公平程度的有效指标。这种经济公平指标通过将社会评估标准与药品安全性和治疗效果分析相结合,有助于完善药品市场的监管框架。